ISSN 1662-4009 (online)

ey0019.2-3 | Neonatal hypoglycaemia | ESPEYB19

2.3. Continuous glucose monitoring in the management of neonates with persistent hypoglycemia and congenital hyperinsulinism

M Win , R Beckett , L Thomson , A Thankamony , K Beardsall

J Clin Endocrinol Metab. 2022 Jan 1;107(1):e246-e253. doi: 10.1210/clinem/dgab601. PMID: 34407200.Brief Summary: This retrospective single center study in neonates with hyperinsulinaemic hypoglycaemia examined the utility of real-time continuous glucose monitoring (CGM). CGM is best placed as an adjunct to routine intermittent blood glucose monitoring, providing information on glucose trends d...

ey0020.2-3 | Important for Clinical Practice | ESPEYB20

2.3. Timing of puberty, pubertal growth, and adult height in short children born small for gestational age treated with growth hormone

EN Upners , LL Raket , JH Petersen , A Thankamony , E Roche , G Shaikh , J Kirk , H Hoey , SA Ivarsson , O Soder , A Juul , RB Jensen

Brief summary: In this study the authors reported the adult height and timing of puberty of a cohort of Danish children born small for gestational age (SGA) and treated with rhGH in comparison with national growth standards. rhGH treatment significantly increased height SDS in adulthood as compared to the height SDS at treatment start. Age at peak height velocity did not differ compared with the reference cohort, although peak height velocity was reduced in SGA subjects. SGA b...

ey0020.8-2 | Clinical Trials – New Treatments | ESPEYB20

8.2. Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes

CK Boughton , JM Allen , J Ware , ME Wilinska , S Hartnell , A Thankamony , T Randell , A Ghatak , REJ Besser , D Elleri , N Trevelyan , FM Campbell , J Sibayan , P Calhoun , R Bailey , G Dunseath , R Hovorka , CLOuD Consortium

Brief summary: In this multicenter, open-label, parallel-group, randomized trial, 97 adolescents (aged 10–16.9 years) were randomized within 21 days after the diagnosis of type 1 diabetes (T1D) to receive either hybrid closed-loop therapy or standard insulin therapy (control) for 24 months. Although closed-loop therapy was associated with better glycemic outcomes, there were no differences in C-peptide between the two groups.The Closed Loop from Ons...

ey0019.10-3 | Clinical Trials | ESPEYB19

10.3. Randomized trial of closed-loop control in very young children with type 1 diabetes

J Ware , JM Allen , CK Boughton , ME Wilinska , S Hartnell , A Thankamony , Beaufort C de , U Schierloh , E Frohlich-Reiterer , JK Mader , TM Kapellen , B Rami-Merhar , M Tauschmann , K Nagl , SE Hofer , FM Campbell , J Yong , KK Hood , J Lawton , S Roze , J Sibayan , J Bocchino , C Kollman , R Hovorka , Consortium KidsAP

N Engl J Med. 2022 Jan 20;386(3):209-219. https://pubmed.ncbi.nlm.nih.gov/35045227/Brief Summary: This multicenter, randomized, crossover trial in 74 very young children (age: 1-7 years) with type 1 diabetes (T1D) tested the safety and efficacy of a hybrid closed-loop system for insulin delivery (CamAPS FX) compared with sensor-augmented pump therapy over 16 weeks. The hybrid closed-loop sy...